drugset / Trial / NCT01342679
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Phase 2
Completed
21 enrolled
Kanto CML Study Group
Epidemiological and Clinical Research Information Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
Timeline
- Start
- 2011-04
- Primary completion
- 2013-03
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |